Bio-Techne Corp TECH

$72.40 0.00 (—)

Valuation

Market cap
11,364,600,000
Revenue TTM
$1,215,040,000
Net income TTM
$181,860,000
PE ratio
42.08
Forward PE
41.79
Profit margin
14.97%
Debt to equity
0.09

Trading

Volume
1,866,600
Avg volume
3,118,176
Day's range
$72.38 – $72.47
Shares out
156,818,000
Stochastic %K
19%
Beta
1.28
Analysts
Sell
Price target
$71.08

Price

Company profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research,...

Show more

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Industry
Biotechnology
Sector
Healthcare
Phone
612 379 8854
Website
https://www.bio-techne.com
Address
614 McKinley Place N.E., Minneapolis, United States

Latest news

Stocktwits

Stocktwits52wHighs Sep 22, 5:46 PM
$TECH printed a new 52-week high today
0 replies
STRelativeStrength Sep 22, 4:20 PM
$TECH undiscovered breakout with 678 watchers
0 replies
TradeSun Sep 20, 6:29 PM
$ALT $APGE $FOLD $TECH It’s not only Tern regarding growing SI into a deal👇
3 replies
VicGold Aug 18, 1:32 AM
$TECH whats the dilly with this 💩?
0 replies
Ramseydog Aug 17, 1:58 PM
🚨 $AIMN AimwellBio just secured a patented Behavioral AI portfolio backed by work involving Oxford Science and a Sanofi pilot. This could be a major step in bringing AI-driven behavioral insights into real-world healthcare applications. 🧠🤖 Patented IP + AI + pharmaceutical validation = a setup worth watching closely. $AIMN $AI $BIOTECH $TECH #AIMN #AI #Biotech #BehavioralAI #Healthcare
0 replies
Estimize Aug 12, 11:09 AM
$TECH reported 0.52 EPS and 321.19 revenue for Q4. http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_content=TECH&utm
0 replies
STRelativeStrength Aug 10, 7:06 PM
$TECH undiscovered breakout with 677 watchers
1 replies
Estimize Aug 5, 10:01 AM
Wall St is expecting 0.44 EPS for $TECH Q1 [Reporting 11/03 BMO] http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_co
0 replies